• Same story, different day...........year ie more of the same fiat floods the world
  • There are no markets
  • "Spreading the ideas of freedom loving people on matters regarding high finance, politics, constructionist Constitution, and mental masturbation of all types"

Genetically Modified Immune Cells Have Killed a Patient, Halting Two Cutting-Edge Trials

Goldhedge

Moderator
Site Mgr
Sr Site Supporter
Joined
Mar 28, 2010
Messages
31,934
Likes
41,428
Location
Rocky Mountains
#1
Whoops!



In staggering setback, toxic reaction kills Cellectis’ first CAR-T patient, forcing trial halt

by john carroll — on September 5, 2017 04:24 AM EDT
Updated: 09:38 AM


The FDA has forced Cellectis $CLLS to slam the brakes on two clinical trials of its off-the-shelf version of a CAR-T therapy after their first patient was killed by a lethally toxic reaction to treatment.

According to the biotech, which is based in Paris with R&D operations in New York, a 78-year-old patient suffering from blastic plasmacytoid dendritic cell neoplasm (BPDCN) died eight days after receiving the biotech’s first dose of the cell therapy. He experienced a lethal reaction as cytokine release syndrome hit, along with a grade 4 case of capillary leak syndrome. A separate study which also treated one patient is underway for acute myeloid leukemia.

The company’s stock was hammered by the bad news, dropping about 30% in pre-market trading and shedding more than $400 million of its market cap.

Significantly, neither of the first two patients treated with UCART123 experienced graft versus host disease, one of the chief fears involved in an allogeneic therapy that takes donated patient cells then adapts them into a ready-to-use therapy, bypassing a complex step required by the first CAR-Ts.

The FDA approved the first personalized CAR-T from Novartis just days ago, and Kite is expected to get an OK of its own soon. But the move by the FDA to slap a hold on these off-the-shelf therapies raises a host of thorny questions for Cellectis.

Juno $JUNO was also forced to halt a study of its lead CAR-T last year — one of the pioneering autologous versions that extracts patient cells and then adapts them before reinfusing them into patients — after patients died from cerebral edema. Then in an astonishingly short period of just a few days, regulators agreed to let researchers proceed with the pivotal trial after a questionable change-up in the preconditioning regimen used to prepare patients for the cell therapy. Almost immediately after treatment resumed, three more patients diedfollowed by a trial halt and the subsequent decision to scrap a drug Juno and the FDA clearly didn’t completely understand.


Will that deadly mistake by regulators force them to be extra sensitive to this quick and early death in the UCART123 studies? Or will regulators be quick to green-light this new therapy back into the study, confident that years of treating CRS — a common reaction among patients receiving CAR-T therapy — can be managed?

Cellectis spelled out the downward spiral experienced by its first patient.

About a week ago, Cellectis reports, the data safety monitoring board suggested lowering the dose — to 6.25×104 UCART123 cells per kilogram — in both studies and capping cyclophosphamide to a total dose of 4g over three days. But the FDA followed up by demanding a halt to the BPDCN study along with the separate study on acute myeloid leukemia, which has also seen one patient treated. That patient experienced a grade 3 case of CRS and a grade 4 case of capillary leak syndrome — both of which resolved within a few days.

Capillary leak syndrome is a condition in which leaky blood vessels can cause a potentially lethal drop in blood pressure.

In the absence of any simple explanation, investors like Biren Amin at Jefferies speculated on causes and defects. His note:

We think there is a chance that CRS events could be mitigated upon lowering the dose of UCART123 beyond the DSMB recommendation and treating CRS symptoms more aggressively, although ultimately we look to more information. These events may be partially due to the UCART123 cells being from a healthy donor but, given the dearth of data, we think CLLS needs to approach through a more holistic approach and utlilizing key research on safety from autologous CAR-T trials over the last 3-4 years. However, we believe the Grd 3 infection (potentially a result of a neutropenic state) and Grd 4 CLS events have the potential to be target specific. For the latter, we note that sAEs involving CLS has been reported for Stemline’s (STML, NC) CD123-directed SL-401 therapeutic. It’s unclear if CLLS also required patients in their studies to have normal ejection fractions and certain pre-specified albumin levels at time of study entry.

Cellectis will get hammered by investors today, particularly as the enthusiasm for all things CAR-T seen in the past few days has swelled everyone’s stock price. Cellectis shares have soared past the $32 mark. The safety issue will challenge CEO André Choulika, a fierce and unabashed proponent of all things Cellectis.

“Cellectis is the first company doing CAR-T,” he told me during an interview at ASCO two years ago. “We are the first gene editing company in the world,” dating back to 1999. “There was no gene editing before us; we are the leaders.”

Today, Cellectis and Choulika will be leading a charge to resolve their biggest challenge to date. It won’t be easy.

SOURCE:
 

Thecrensh

Gold Member
Gold Chaser
Joined
Jun 26, 2013
Messages
4,513
Likes
5,135
#2
This is the problem with GM...do the genetic scientists REALLY know what the hell they are doing or are they merely the modern equivalent of medieval alchemists who are literally tinkering with the planet?
 

the_shootist

Molon Labe!
Midas Member
Sr Site Supporter
Joined
May 31, 2015
Messages
21,932
Likes
24,799
#3
Whoops!



In staggering setback, toxic reaction kills Cellectis’ first CAR-T patient, forcing trial halt

by john carroll — on September 5, 2017 04:24 AM EDT
Updated: 09:38 AM


The FDA has forced Cellectis $CLLS to slam the brakes on two clinical trials of its off-the-shelf version of a CAR-T therapy after their first patient was killed by a lethally toxic reaction to treatment.

According to the biotech, which is based in Paris with R&D operations in New York, a 78-year-old patient suffering from blastic plasmacytoid dendritic cell neoplasm (BPDCN) died eight days after receiving the biotech’s first dose of the cell therapy. He experienced a lethal reaction as cytokine release syndrome hit, along with a grade 4 case of capillary leak syndrome. A separate study which also treated one patient is underway for acute myeloid leukemia.

The company’s stock was hammered by the bad news, dropping about 30% in pre-market trading and shedding more than $400 million of its market cap.

Significantly, neither of the first two patients treated with UCART123 experienced graft versus host disease, one of the chief fears involved in an allogeneic therapy that takes donated patient cells then adapts them into a ready-to-use therapy, bypassing a complex step required by the first CAR-Ts.

The FDA approved the first personalized CAR-T from Novartis just days ago, and Kite is expected to get an OK of its own soon. But the move by the FDA to slap a hold on these off-the-shelf therapies raises a host of thorny questions for Cellectis.

Juno $JUNO was also forced to halt a study of its lead CAR-T last year — one of the pioneering autologous versions that extracts patient cells and then adapts them before reinfusing them into patients — after patients died from cerebral edema. Then in an astonishingly short period of just a few days, regulators agreed to let researchers proceed with the pivotal trial after a questionable change-up in the preconditioning regimen used to prepare patients for the cell therapy. Almost immediately after treatment resumed, three more patients diedfollowed by a trial halt and the subsequent decision to scrap a drug Juno and the FDA clearly didn’t completely understand.


Will that deadly mistake by regulators force them to be extra sensitive to this quick and early death in the UCART123 studies? Or will regulators be quick to green-light this new therapy back into the study, confident that years of treating CRS — a common reaction among patients receiving CAR-T therapy — can be managed?

Cellectis spelled out the downward spiral experienced by its first patient.

About a week ago, Cellectis reports, the data safety monitoring board suggested lowering the dose — to 6.25×104 UCART123 cells per kilogram — in both studies and capping cyclophosphamide to a total dose of 4g over three days. But the FDA followed up by demanding a halt to the BPDCN study along with the separate study on acute myeloid leukemia, which has also seen one patient treated. That patient experienced a grade 3 case of CRS and a grade 4 case of capillary leak syndrome — both of which resolved within a few days.

Capillary leak syndrome is a condition in which leaky blood vessels can cause a potentially lethal drop in blood pressure.

In the absence of any simple explanation, investors like Biren Amin at Jefferies speculated on causes and defects. His note:

We think there is a chance that CRS events could be mitigated upon lowering the dose of UCART123 beyond the DSMB recommendation and treating CRS symptoms more aggressively, although ultimately we look to more information. These events may be partially due to the UCART123 cells being from a healthy donor but, given the dearth of data, we think CLLS needs to approach through a more holistic approach and utlilizing key research on safety from autologous CAR-T trials over the last 3-4 years. However, we believe the Grd 3 infection (potentially a result of a neutropenic state) and Grd 4 CLS events have the potential to be target specific. For the latter, we note that sAEs involving CLS has been reported for Stemline’s (STML, NC) CD123-directed SL-401 therapeutic. It’s unclear if CLLS also required patients in their studies to have normal ejection fractions and certain pre-specified albumin levels at time of study entry.

Cellectis will get hammered by investors today, particularly as the enthusiasm for all things CAR-T seen in the past few days has swelled everyone’s stock price. Cellectis shares have soared past the $32 mark. The safety issue will challenge CEO André Choulika, a fierce and unabashed proponent of all things Cellectis.

“Cellectis is the first company doing CAR-T,” he told me during an interview at ASCO two years ago. “We are the first gene editing company in the world,” dating back to 1999. “There was no gene editing before us; we are the leaders.”

Today, Cellectis and Choulika will be leading a charge to resolve their biggest challenge to date. It won’t be easy.

SOURCE:
Play stupid games, win stupid prizes. As an unreligious old coot, I must say that this is some bold shit to be doing. If there is a God he's not going to like us moving in on his action and it will all end badly for us, be it His will or simply karma!
 

gringott

Killed then Resurrected
Midas Member
Site Supporter ++
Joined
Apr 2, 2010
Messages
14,929
Likes
19,507
Location
You can't get there from here.
#7
Hey, the guy died during experimentation to help him. 78 years old, was suffering from blastic plasmacytoid dendritic cell neoplasm (BPDCN), which I don't know WTF that is but sounds deadly. Anybody think he was going to live to 100?

I'm more concerned with the actual damage done by fake science such as the campaign against natural fats and meat, HFCS in everything, soda pop paid for with food stamps, and for anti-cholesterol drugs which seem to be causing Type II diabetes. Anybody notice the truth about cholesterol did not even start to come out until the patents on this class of drugs ran out?